NLRPs and tumor: research progress from molecular mechanisms to clinical applications

Luhao Song1,2, Yanlin Cao3, Yongguang Tao4,5

  • 1The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Hunan Key Laboratory of Cancer Metabolism, Central South University, Changsha, Hunan, China.

Oncogene
|November 26, 2025
PubMed

Insights

NOD-like receptor proteins (NLRPs) are crucial for immune balance and anti-tumor immunity by forming inflammasomes and activating caspase-1. This review explores NLRP roles in cancer, their regulation, and therapeutic potential.

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • NOD-like receptor proteins (NLRPs) are key components of the innate immune system.
  • NLRPs regulate apoptosis, inflammation, and immune balance by detecting cellular disturbances.
  • They are crucial for inflammasome formation and activation of caspase-1.

Purpose of the Study:

  • To review the diverse roles of NLRPs in various cancer types.
  • To outline the regulatory networks controlling NLRP activity.
  • To discuss the clinical implications of NLRPs in cancer for therapeutic development.

Main Methods:

  • Literature review of NLRP function in cancer.
  • Analysis of NLRP regulatory mechanisms.
  • Examination of clinical relevance and therapeutic strategies.

Main Results:

  • NLRPs play multifaceted roles in different cancer types.
  • Inflammasome activation by NLRPs is critical for anti-tumor immunity via IL-1β and IL-18.
  • Complex regulatory networks govern NLRP activity.

Conclusions:

  • NLRPs are significant regulators of immune responses in cancer.
  • Understanding NLRP pathways offers potential for novel cancer therapies.
  • Targeting NLRPs could enhance anti-tumor immunity.

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.7K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K